Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Compugen Ltd.
  6. News
  7. All News
    CGEN   IL0010852080

COMPUGEN LTD.

(CGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about COMPUGEN LTD.
01/18Compugen Awarded US Patent for Method of Use of Cancer Drug Candidate
MT
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
PR
01/18Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering T..
CI
2021Compugen Presents Preliminary Translational Data Demonstrating Immune Activation in the..
PR
2021Compugen Wins Fortinet Achievement Award at NSE XPERTS Summit 2021
AQ
2021Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating
MT
2021COMPUGEN : Q3 Earnings Snapshot
AQ
2021Compugen Narrows Net Loss in Q3, Revenue Gains on Milestone Payment
MT
2021Press Release dated November 12, 2021 – “Compugen Presents Preliminary Resu..
PU
2021Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PU
2021Compugen Presents Preliminary Results from Phase 1 Dose Escalation Monotherapy Study of..
PR
2021Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
PR
2021Compugen Presents Preliminary Results from Phase 1/2 Dose Escalation Study of COM701 wi..
PR
2021Compugen Reports Third Quarter 2021 Results
PR
2021Compugen Presents Initial Translational Data Supporting the Differentiation of PVRIG Co..
CI
2021Compugen Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2021Health Care Stocks Still Edging Lower Just Ahead of Thursday Close
MT
2021Health Care Stocks Sinking Thursday
MT
2021Compugen Receives $20 Million Investment From Bristol Myers; Shares Rise
MT
2021Wall Street Set for Rebound After Sell-Off Fueled by Inflation Concerns
MT
2021Compugen Shares Rise 18% Premarket After Bristol Myers Investment
DJ
2021Compugen Announces Collaboration Expansion with Bristol Myers Squibb alongside $20 Mill..
PR
2021Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Mill..
CI
2021Compugen Ltd. announced that it has received $19.999993 million in funding from Bristol..
CI
2021Compugen Ltd. announced that it expects to receive $20 million in funding from Bristol-..
CI
2021Compugen to Present at Upcoming Investor Conferences
PR
2021Compugen to Release Third Quarter 2021 Results on Friday, November 12, 2021
PR
2021COMPUGEN : Expects $6 Million Milestone Payment From AstraZeneca for First Patient Dosed i..
MT
2021COMPUGEN : Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed w..
PR
2021Compugen Ltd. Announces Milestone Payment from AstraZeneca Triggered by First Patient D..
CI
2021COMPUGEN : To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combinat..
PR
2021COMPUGEN : Awarded Top 50 Most Promising Microsoft Solution Providers by CIOReview
AQ
2021COMPUGEN : to Present at the Cantor Global Healthcare Conference
PU
2021COMPUGEN : to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
PR
2021COMPUGEN : Says AstraZeneca Will Launch Study on Lung Cancer Drug Candidate Based on Its C..
MT
2021COMPUGEN : Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
PR
2021Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Developmen..
CI
2021COMPUGEN : Q2 Loss Widens as Expenses Climb
MT
2021COMPUGEN : Q2 Earnings Snapshot
AQ
2021COMPUGEN : Reports Second Quarter 2021 Results (Form 6-K)
PU
2021COMPUGEN : Reports Second Quarter 2021 Results
PR
2021Compugen Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
2021COMPUGEN : Doses First Patient in Expansion Arm of Study Evaluating Triple Combination Ant..
MT
2021COMPUGEN : Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 ..
PR
2021Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701..
CI
2021COMPUGEN : Commences Dosing in Phase 1 Trial of Combo Therapy for Advanced Malignancies
MT
2021COMPUGEN : Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patien..
PR
2021Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patie..
CI
2021COMPUGEN : to Release Second Quarter 2021 Results on Wednesday, July 28, 2021
PR
2021COMPUGEN : Doses First Patient in Study of Combination Therapy to Treat Solid Tumors; Shar..
MT
2021COMPUGEN : Doses First Patient in COM701/Opdivo« (nivolumab) Phase 1b Cohort Expansion Stu..
PR
2021Compugen Doses First Patient in COM701/Opdivo« Phase 1b Cohort Expansion Study
CI
2021COMPUGEN : Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in ..
PR
2021Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoi..
CI
2021COMPUGEN : Preliminary biomarker data reveal immune activation evidenced by a trend of inc..
PU
2021COMPUGEN : Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG..
PR
2021Compugen Ltd. Updates Data from Phase 1 Study of COM701
CI
2021COMPUGEN : Q1 Net Loss Widens; Shares Rise 5% Pre-Bell
MT
2021COMPUGEN : Q1 Earnings Snapshot
AQ
2021Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
2021COMPUGEN TO PARTICIPATE AT SITC'S TA : A Deep Dive Seminar Series
PR
2021COMPUGEN : Expands Research Collaboration with Johns Hopkins University for Novel Tumor Gr..
MT
2021COMPUGEN : Announces Expansion of Research Collaboration with Johns Hopkins University for..
PR
2021Compugen Ltd. Announces Expansion of Research Collaboration with Johns Hopkins Universi..
CI
2021COMPUGEN : to Release First Quarter 2021 Results on Thursday, May 13, 2021
PR
2021COMPUGEN : Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Can..
PR
2021Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Ca..
CI
2021COMPUGEN : SVB Leerink Adjusts Price Target on Compugen to $16 From $19, Maintains Outperf..
MT
2021COMPUGEN : to Present at the Oppenheimer 31st Annual Healthcare Conference
PR
2021COMPUGEN : Annual Report (SEC Filing - 20-F)
PU
2021COMPUGEN : Q4 Loss Flat, Operating Expenses Rise
MT
2021COMPUGEN : 4Q Earnings Snapshot
AQ
2021Compugen Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
CI
2021COMPUGEN : Reports Fourth Quarter and Full Year 2020 Results
PR
2021Compugen Ltd. Announces Data Update from Com701 Phase 1 Clinical Trial
CI
1  2  3  4  5Next
Upcoming event on COMPUGEN LTD.